STEVE ASELAGE
CIK 1221599 · Chief Executive Officer · last filed 2024-06-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$17.93M
Companies
7
Total Filings
114
Lifetime Open-Market Net
-$21.13M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BCRX | Director | 72,659 | $8.70 | $632.1K | $65.1K | 23 | 2024-06-14 |
| Acer Therapeutics Inc. (ACER) Delisted | Director | 483,741 | $0.66 | $319.3K | $696.7K | 9 | 2023-03-16 |
| TVTX | Director | 166,419 | $52.04 | $8.66M | -$4.97M | 12 | 2022-05-12 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 233,732 | — | — | -$3.46M | 32 | 2020-11-06 |
| Acer Therapeutics Inc. (ACERW) Delisted | Director | 13,905 | — | — | $24.0K | 2 | 2017-12-18 |
| Acer Therapeutics Inc. (OPXAW) Delisted | Director | 11,905 | — | — | $0 | 1 | 2017-09-21 |
| BMRN | EVP, Chief Business Officer | 154,375 | $55.95 | $8.64M | -$13.49M | 33 | 2012-07-05 |
Recent Filings · Page 8 of 12
114 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-06-14 | Travere Therapeutics, Inc. (RTRX) Delisted | Buy (P) | −5,000 | -$89.2K | EDGAR |
| 2017-05-18 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-11-23 | Travere Therapeutics, Inc. (RTRX) Delisted | Mixed | −65,200 | -$173.2K | EDGAR |
| 2016-05-23 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-01-29 | Travere Therapeutics, Inc. (RTRX) Delisted | Gift (G) | −3,000 | $0 | EDGAR |
| 2015-11-12 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −60,000 | -$1.12M | EDGAR |
| 2015-09-15 | Travere Therapeutics, Inc. (RTRX) Delisted | Gift (G) | −3,000 | $0 | EDGAR |
| 2015-07-02 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-11-21 | Travere Therapeutics, Inc. (RTRX) Delisted | Buy (P) | +10,000 | $84.6K | EDGAR |
| 2014-11-10 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +100,000 | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.